Medicinova Inc Common Stock (MNOV)

FairStock Score: 43/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and sell below intrinsic value. MediciNova does not fit that mold. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $458,439 and a net loss of $2.3 million. The prior quarter, fiscal Q1 2026 ended 2026-03-31, had revenue of $186,984 and a net loss of $2.6 million. For FY2025 ended 2025-12-31, revenue was $409,657 and net loss was $12.0 million; FY2024 net loss was $11.0 million, and FY2023 revenue was $1.0 million with a net loss of $8.6 million. This is a clinical-stage biotech with six employees, one main Phase 2 candidate, and no record of profits. The FairStock Lynch category is none because it lost money in each of the last four years. The balance sheet shows no debt (D/E 0.00), and Piotroski is 6/9, which is a modest positive. The overall FairStock score is 43/100. But trailing free cash flow is -$9.1 million and the FCF yield is -12.4%; Altman is -0.87. At the 2026-10-13 close of $1.50, FairStock calculates P/B at 1.97 and P/E at -7.14, neither of which provides a Graham-style margin of safety. There is no dividend. Revenue is rising sequentially, but from a tiny base, and every dollar of sales is overwhelmed by losses. The investment case rests almost entirely on future trial outcomes, not on present earnings or a durable moat. I would need far more evidence of commercial success before calling this a business rather than a lottery ticket.

In plain English: MediciNova is a tiny drug company with six workers trying to develop a medicine for serious nerve and brain diseases. It has no profits and loses money, even though it has some revenue and no debt. At $1.50, the stock price is not supported by current earnings or sales, so it looks speculative rather than cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer